Celebrex Label Adds Cardiovascular Risk Language
This article was originally published in The Pink Sheet Daily
Executive Summary
Celecoxib labeling revision includes long-term safety data from three celecoxib trials, one of which suggests increased cardiovascular risk. Celebrex also gains ankylosing spondylitis indication.
You may also be interested in...
Celebrex Polyp Trial Meta-Analysis Finds CV Risk In Line With Previous Findings
Analysis of cardiovascular risk in the APC and PreSAP trials is consistent with current labeling warnings, firm asserts.
Celebrex Polyp Trial Meta-Analysis Finds CV Risk In Line With Previous Findings
Analysis of cardiovascular risk in the APC and PreSAP trials is consistent with current labeling warnings, firm asserts.
NSAID Safety Data Merit No Further Action, EMEA Committee Says
However, the Committee for Medicinal Products for Human Use recommends consistent labeling at the national level.